 | Up a level |
Cano, Antonio; Nappi, Rossella E; Santoro, Nanette; Stute, Petra; Blogg, Martin; English, Marci L; Morga, Antonia; Scrine, Ludmila; Siddiqui, Emad; Ottery, Faith D (2024). Fezolinetant impact on health-related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials. BJOG : an international journal of obstetrics and gynaecology, 131(9), pp. 1296-1305. Wiley 10.1111/1471-0528.17773
Lensen, Sarah; Paramanandam, Vincent S; Gabes, Michaela; Kann, Gesina; Donhauser, Theresa; Waters, Niamh F; Li, Anna D; Peate, Michelle; Susanto, Nipuni S; Caughey, Lucy E; Rangoonwal, Fatema; Liu, Jingbo; Condron, Patrick; Anagnostis, Panagiotis; Archer, David F; Avis, Nancy E; Bell, Robin J; Carpenter, Janet S; Chedraui, Peter; Christmas, Monica; ... (2024). Recommended measurement instruments for menopausal vasomotor symptoms: the COMMA (Core Outcomes in Menopause) consortium. Menopause, 31(7), pp. 582-590. The North American menopause Society 10.1097/GME.0000000000002370
Paramanandam, Vincent S; Lensen, Sarah; Gabes, Michaela; Kann, Gesina; Donhauser, Theresa; Waters, Niamh F; Li, Anna D; Peate, Michelle; Susanto, Nipuni S; Caughey, Lucy E; Rangoonwal, Fatema; Liu, Jingbo; Condron, Patrick; Obalowu, Ismaila Aberi; Archer, David F; Bell, Robin J; Christmas, Monica; Davies, Melanie; Davis, Susan R; Giblin, Karen; ... (2024). Recommended measurement instruments for genitourinary symptoms associated with menopause: the COMMA (Core outcomes in menopause) consortium. Menopause, 31(7), pp. 591-599. The North American menopause Society 10.1097/GME.0000000000002369
Nappi, Rossella E; Johnson, Kimball A; Stute, Petra; Blogg, Martin; English, Marci; Morga, Antonia; Scrine, Ludmila; Siddiqui, Emad; Ottery, Faith D (2024). Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2). Menopause, 31(6), pp. 512-521. The North American menopause Society 10.1097/GME.0000000000002354
Johnson, Kimball A; Martin, Nancy; Nappi, Rossella E; Neal-Perry, Genevieve; Shapiro, Marla; Stute, Petra; Thurston, Rebecca C; Wolfman, Wendy; English, Marci; Franklin, Catherine; Lee, Misun; Santoro, Nanette (2023). Efficacy and Safety of Fezolinetant in Moderate-to-Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT. The Journal of clinical endocrinology and metabolism, 108(8), pp. 1981-1997. The Endocrine Society 10.1210/clinem/dgad058
Panay, Nick; Nappi, Rossella E; Stute, Petra; Palacios, Santiago; Paszkowski, Tomasz; Kagan, Risa; Archer, David F; Héroux, Julie; Boolell, Mitra (2023). Oral estradiol/micronized progesterone may be associated with lower risk of venous thromboembolism compared with conjugated equine estrogens/medroxyprogesterone acetate in real-world practice. Maturitas, 172, pp. 23-31. Elsevier 10.1016/j.maturitas.2023.04.004
Merki-Feld, Gabriele S; Sandor, Peter S; Nappi, Rossella E; Pohl, Heiko; Schankin, Christoph (2022). Clinical features of migraine with onset prior to or during start of combined hormonal contraception: a prospective cohort study. Acta neurologica Belgica, 122(2), pp. 401-409. Springer 10.1007/s13760-021-01677-3
Lensen, Sarah; Bell, Robin J; Carpenter, Janet S; Christmas, Monica; Davis, Susan R; Giblin, Karen; Goldstein, Steven R; Hillard, Tim; Hunter, Myra S; Iliodromiti, Stamatina; Jaisamrarn, Unnop; Khandelwal, Sunila; Kiesel, Ludwig; Kim, Bobae V; Lumsden, Mary Ann; Maki, Pauline M; Mitchell, Caroline M; Nappi, Rossella E; Niederberger, Craig; Panay, Nick; ... (2021). A core outcome set for genitourinary symptoms associated with menopause: the COMMA (Core Outcomes in Menopause) global initiative. Menopause, 28(8), pp. 859-866. The North American menopause Society 10.1097/GME.0000000000001788
